Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian R Murphy

Showing results (71-80 of 122) with videos related to

Pageof 13
Sort By:
Virology|August 2, 2003
A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4Kathryn A Hanley, Luella R Manlucu, Lara E Gilmore, et al.
Journal of Virology|January 5, 2002
Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backboneAlexander C Schmidt, Daniel R Wenzke, Josephine M McAuliffe, et al.
Virology|August 31, 2002
Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cellsJoseph E Blaney, Daniel H Johnson, Gracielle G Manipon, et al.
Virus Genes|April 4, 2002
Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse geneticsJason T Newman, Sonja R Surman, Jeffrey M Riggs, et al.
Human Vaccines|October 3, 2006
The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteersAnna P Durbin, Julie McArthur, Jennifer A Marron, et al.
Vaccine|June 14, 2005
Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeysEmmalene J Bartlett, Emerito Amaro-Carambot, Sonja R Surman, et al.
Journal of Virology|February 14, 2006
A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challengeAlexander Bukreyev, Lijuan Yang, Sherif R Zaki, et al.
Vaccine|August 17, 2004
Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunityKathryn A Hanley, Luella R Manlucu, Gracielle G Manipon, et al.
Vaccine|September 25, 2003
Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cellsJoseph E Blaney, Gracielle G Manipon, Cai Yen Firestone, et al.
Journal of Virology|January 30, 2004
Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitroJosephine M McAuliffe, Sonja R Surman, Jason T Newman, et al.
Pageof 13

Showing results (71-80 of 122) with videos related to

Sort By:
Pageof 13
Virology|August 2, 2003
A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4Kathryn A Hanley, Luella R Manlucu, Lara E Gilmore, et al.
Journal of Virology|January 5, 2002
Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backboneAlexander C Schmidt, Daniel R Wenzke, Josephine M McAuliffe, et al.
Virology|August 31, 2002
Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cellsJoseph E Blaney, Daniel H Johnson, Gracielle G Manipon, et al.
Virus Genes|April 4, 2002
Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse geneticsJason T Newman, Sonja R Surman, Jeffrey M Riggs, et al.
Human Vaccines|October 3, 2006
The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteersAnna P Durbin, Julie McArthur, Jennifer A Marron, et al.
Vaccine|June 14, 2005
Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeysEmmalene J Bartlett, Emerito Amaro-Carambot, Sonja R Surman, et al.
Journal of Virology|February 14, 2006
A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challengeAlexander Bukreyev, Lijuan Yang, Sherif R Zaki, et al.
Vaccine|August 17, 2004
Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunityKathryn A Hanley, Luella R Manlucu, Gracielle G Manipon, et al.
Vaccine|September 25, 2003
Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cellsJoseph E Blaney, Gracielle G Manipon, Cai Yen Firestone, et al.
Journal of Virology|January 30, 2004
Codon substitution mutations at two positions in the L polymerase protein of human parainfluenza virus type 1 yield viruses with a spectrum of attenuation in vivo and increased phenotypic stability in vitroJosephine M McAuliffe, Sonja R Surman, Jason T Newman, et al.
Pageof 13